GSK has made good on its promise to invest in the UK, confirming plans to spend £500m ($789m) on new manufacturing capacity in the country just a day after the Government introduced a tax ‘patent box.'
Quintiles has invested £3m ($4.6m) in a new UK-based biomarker R&D company in a continuation of its efforts to build in the field of personalised medicines.
Stevanato Group has pulled forward the expansion of its EZ-Fill facility in Italy by one year in a bid to dominate a bigger portion of the “rapidly expanding” ready-to-fill vials market.
The drug industry's need to improve product quality while reducing production costs is driving global demand for testing technologies according to Sepha.
Piramal Healthcare has added commercial-scale antibody-drug-conjugate (ADC) manufacturing capacity at its UK plant predicting increasing demand for this specialist type of contracting.
Pharmaceutical intermediate sales helped Codexis in Q1 but the US biocatalysis specialist still posted a net loss for the quarter on higher R&D spending
Oystar has sold its processing tech units, Huttlin and Manesty, to Bosch in a deal that continues its effort to refocus on primary and secondary packaging.
Unilife has begun a ‘scheduled realignment’ of its operating infrastructure to support the production and sale of its Unifill prefilled syringe, according to a statement released by the company.
Cytovance Biologics, the US-based biopharmaceutical contract manufacturer (CMO), has secured a growth equity investment from Connecticut, US-based private investors, Great Point Partners.
US drug giant Pfizer may sell its generics, consumer health and Capsugel units in an effort to slim down and refocus on its core pharmaceutical business according to a number of reports.
India-headquartered pharmaceutical packaging manufacturer Bilcare has rolled out a new unit, Bilcare Research, which merges its existing films and foil businesses with those of recent acquisition Ineous Films.
IMS Health predicts China will become the world’s second largest pharmaceutical market by 2015 due to robust economic growth and healthcare reforms that allow for increased spending on drugs.
Pharmaceutical manufacturers should consider solvent recovery as the US government looks to establish mandates for greenhouse gas emissions, according to Rockwell Automation.
Vetter Pharma have begun construction of its latest storage facility in a move that forms part of Vetter’s recent efforts to expand its pharmaceutical logistical resources. Vetter's newest facility, located in Germany, adds to another new U.S facility...
Nampak Europe is to invest €4.5m ($5.4m) in a new purpose-built factory to replace its Wolfen facility in a move to reduce product costs in the northern European arm of the business.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
DPT Laboratories has added bulk production and packaging capacity at its liquid and semi-solids plant in San Antonio, Texas in a continuation of its recent manufacturing reorganisation.
Archimica has entered into an exclusive distribution agreement with a Merck KGaA subsidiary to provide building blocks and special reagents for organic synthesis.
A significant share of contract API maker ScinoPharm Taiwan is set to change hands after Watson Pharmaceuticals decided to sell its stake to Uni-President Enterprises Corporation.
The impact of the economic downturn is still being felt but SAFC remains "cautiously optimistic" about 2010, believing its close relationships with clients and investment in key emerging markets will generate business.
Dow has joined with Signet Healthcare Partners to form a new independent company which will use the chemical company’s Pfenex protein expression technology to accelerate development.
The splitting up of MDS Pharma Services had little impact on the remaining business as there was limited integration anyway, according to a VP who detailed how the divestitures have allowed resources to be focused on core strengths.
Gerresheimer is increasing its presence in the pharmaceutical plastics business, which it believes is increasingly important, by opening an R&D centre in the US and a production facility in Spain.
US CRO and central laboratory services provider Pacific Biometrics (PBI) has entered into a $4m (€2.7m) loan agreement that it says will help further the development of its contract biomarkers business.
Summit has sold Dextra, its analytical and manufacturing services division, to NZP but believes operating the contract business has been beneficial to its industry standing and R&D capabilities.
US private equity group Water Street Healthcare Partners (WSHP) says its purchase of AAIPharma’s pharmaceutical development business was a “unique opportunity” to invest in an expanding market.
